Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 5, 1997, Pages 544-553

  Borin, Marie T ^a   Chambers, James H ^a   Carel, Barbara J ^a   Gagnon, Suzanne ^a   Freimuth, William W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CD4 ANTIGEN; COTRIMOXAZOLE; CYTOCHROME P450; DELAVIRDINE; DIPHENHYDRAMINE; DRUG METABOLITE; HYDROCORTISONE; HYDROXYZINE; RIFAMPICIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LYMPHOCYTE COUNT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; ALKYLATION; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DELAVIRDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HIV SEROPOSITIVITY; HUMANS; HYDROCORTISONE; INDOLES; LIVER; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; PIPERAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN;

EID: 0030911953     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90134-X     Document Type: Article

References (25)

1. Romero DL, Busso M, Tan CK, Reusser F, Palmer JR, Poppe SM, et al. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1991;8:8806-10.
2. Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey KM, et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993;37:1127-31.
3. Chong KT, Pagano PJ, Hinshaw RR. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits HIV-1 replication in vitro. Antimicrob Agents Chemother 1994;38:288-93.
4. Batts DH, Freimuth WW, Cox SR, Peel BG, Hanover CK, Wathen LK, et al. Open-label escalating multiple-dose study of the safety, tolerance and pharmacokinetics of oral U-90152S (delavirdine, DLV) in HIV-1 infected males and females who are maintained on a stable dose of AZT [abstract]. Presented at the First National Conference on Human Retroviruses and Related Infections, Washington, DC, December 12-16, 1993.
5. Freimuth WW, Wathen LK, Cox SR, Chuang-Stein CJ, Greenwald CA, Daenzer CL, et al. Delavirdine (DLV) in combination with zidovudine (ZDV) causes sustained antiviral and immunological effects in HIV-1 infected individuals [abstract]. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 29-February 1, 1996.
6. Freimuth WW, Chuang-Stein CJ, Greenwald CA, Cox SR, Edge-Padbury BA, Carberry PA, et al. Delavirdine (DLV) plus didanosine (ddl) combination therapy has sustained surrogate marker response in advanced HIV-1 population [abstract]. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 29-February 1, 1996.
7. Venkatesan K. Pharmacokinetic drug interactions with rifampicin, Clin Pharmacokinet 1992;22:47-65.
8. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions. Arch Intern Med 1992; 152:711-16.
9. Bolt HM, Kappus H, Bolt M. Effect of rifampicin treatment on the metabolism of oestradiol and 17-ethynyloestradiol by human liver microsomes. Eur J Clin Pharmacol 1975;8:301-7.
10. Okey A. Enzyme induction in the cytochrome P450 system. Pharmacol Ther 1990;45:241-98.
11. Park BK, Breckenridge AM. Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 1981;6:1-24.
12. Baciewicz AM, Self TH. Rifampin drug interactions. Arch Intern Med 1984;144:1667-71.
13. Acocella G, Pagani V, Marchetti M, Baroni GC, Nicolis FB. Kinetic studies on rifampicin. Chemotherapy 1971;16:356-70.
14. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-27.
15. Cheng CL, Smith DE, Cox SR, Watkins PB, Blake DS, Carver PL, et al. Correlation between ERMBT and oral exposure to delavirdine mesylate in HIV-positive patients [abstract]. Pharm Res 1995;12:S374.
16. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, et al. The increase in urinary excretion of 6-β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28:373-87.
17. Staton BA, Johnson MG, Friis JM, Adams WJ. Simple, rapid, and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. J Chromatogr B Biomed Appl 1995;668:99-106.
18. Staton BA, Friis JM, Carel BJ, Rettig J, Hanson G, Adams WJ. Determination of delavirdine and metabolite in human plasma by HPLC with fluorescence detection [abstract]. Pharm Res 1994;11:S19.
19. Lau YY, Hanson GD, Carel BJ. Determination of rifampin by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 1996;676:147-52.
20. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75.
21. Voorman RL, Maio SM, Wang X. Mechanism-based inactivation of rat and human cytochrome P450 3A by delavirdine [abstract]. Presented at the Ninth International Conference on Cytochrome P450, Zurich, Switzerland, July 23-27, 1995.
22. Borin MT, Cox SR, Driver MR, Freimuth WW, Aksentijevich S, Piergies AA. Effect of rifabutin on delavirdine pharmacokinetics in HIV+ patients [abstract]. Presented at the Thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 4-7, 1994.
23. Perucca E, Grimaldi R, Frigo GM, Sardi A, Monig H, Ohnhaus EE. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988;34:595-9.
24. Doble N, Shaw R, Rowland-Hill C, Lush M, Warnock DW, Keal EE. Pharmacokinetic study of the interaction between rifampicin and ketoconazole. J Antimicrob Chemother 1988;21:633-5.
25. Garg SK, Chakrabarti A, Panigrahi D, Sharma M, Talwar P, Kumar N, et al. Comparative bioavailability and in vitro antimicrobial activity of two different brands of rifampicin. Eur J Drug Metab Pharmacokinet 1991;16:223-9.